- Home
- PBYI vs NVRO Comparison
PBYI vs NVRO Comparison
Compare PBYI & NVRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- NVRO
- Stock Information
- Founded
- PBYI 2010
- NVRO 2006
- Country
- PBYI United States
- NVRO United States
- Employees
- PBYI N/A
- NVRO N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- NVRO Medical/Dental Instruments
- Sector
- PBYI Health Care
- NVRO Health Care
- Exchange
- PBYI Nasdaq
- NVRO Nasdaq
- Market Cap
- PBYI 153.2M
- NVRO 139.0M
- IPO Year
- PBYI N/A
- NVRO 2014
- Fundamental
- Price
- PBYI $2.97
- NVRO $4.57
- Analyst Decision
- PBYI Strong Buy
- NVRO Hold
- Analyst Count
- PBYI 1
- NVRO 14
- Target Price
- PBYI $7.00
- NVRO $7.97
- AVG Volume (30 Days)
- PBYI 821.3K
- NVRO 572.2K
- Earning Date
- PBYI 02-27-2025
- NVRO 02-19-2025
- Dividend Yield
- PBYI N/A
- NVRO N/A
- EPS Growth
- PBYI 492.79
- NVRO N/A
- EPS
- PBYI 0.47
- NVRO N/A
- Revenue
- PBYI $243,569,000.00
- NVRO $419,146,000.00
- Revenue This Year
- PBYI N/A
- NVRO N/A
- Revenue Next Year
- PBYI N/A
- NVRO $0.64
- P/E Ratio
- PBYI $6.38
- NVRO N/A
- Revenue Growth
- PBYI 6.30
- NVRO N/A
- 52 Week Low
- PBYI $2.23
- NVRO $3.17
- 52 Week High
- PBYI $7.73
- NVRO $19.47
- Technical
- Relative Strength Index (RSI)
- PBYI 45.95
- NVRO 60.51
- Support Level
- PBYI $2.92
- NVRO $3.17
- Resistance Level
- PBYI $4.06
- NVRO $3.99
- Average True Range (ATR)
- PBYI 0.27
- NVRO 0.33
- MACD
- PBYI -0.03
- NVRO 0.13
- Stochastic Oscillator
- PBYI 4.39
- NVRO 93.98
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About NVRO Nevro Corp.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.